Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Kevkan, not sure that’s right. You can apply for more than your entitlement under the open offer but at £1.75 per share. You can’t be forced to buy at a higher price. If you don’t get some or all of any additional shares, you could just withdraw the cash again.
The Open Offer is for £7m of shares, which is 4m shares at £1.75 per share.
Total number of shares in issue is 149,433,442.
(number of shares you hold/149,433,442) x 4,000,000 = your entitlement
I was a little worried when I saw the placing RNS but then I read it...it's a barnstormer.
As well as the points Dibs mentioned, the RNS says "Interactions with the European Medicines Agency (“EMA”) are ongoing."
Looks like the Recovery trial should have gone with SNG001 instead of replacing it with azithromycin - this has just been published in the Lancet https://doi.org/10.1016/S0140-6736(20)31862-6
“In patients with severe COVID-19, adding azithromycin to standard of care treatment (which included hydroxychloroquine) did not improve clinical outcomes. Our findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19.“
Do you really think it will hit 10p tomorrow?!
Clinigen provides some background on MAPs at https://www.clinigengroup.com/insights/2017/supplementing-clinical-development-with-a-managed-access-program/
It feels to me that the touch paper has been lit today...
Sir Jeremy Farrar, director of the Wellcome Trust and member of SAGE, has just tweeted about one of the studies mentioned in the Guardian article, https://twitter.com/JeremyFarrar/status/1309208351553847297?s=20 saying:
"The ability to control the initial infection through type I IFN may be so important in COVID and also many other acute viral infections - Flu, Dengue, Yellow Fever, Chik, and others."
The study is here https://science.sciencemag.org/content/early/2020/09/23/science.abd4570
Perhaps a good time to look back at https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-data-readout-final-version.pdf
Thanks sollodgeblue - great spot.
Tried filters for the first time today - amazing how adding a few names (who usually turn up together) vastly improves the experience ;o)
Worth a read, from the BMJ https://www.bmj.com/content/370/bmj.m3720
“ People infected with both flu and SARS-CoV-2 are more than twice as likely to die as someone with the new coronavirus alone, emerging evidence from England has shown.
An analysis by Public Health England (PHE) of cases from January to April 2020 also found that people with the two viruses were more at risk of severe illness. Most cases of coinfection were in older people, and more than half of them died.
...
Yvonne Doyle, medical director of PHE, told the briefing, “There is some evidence to suggest that flu and covid and other viruses may compete with each other. [But] if you get both, you are in some serious trouble. And the people who are most likely to get both may be the very people that can least afford to.”
Great stuff WedME.
As part of the consultation on The Human Medicines (Coronavirus) (Amendment) Regulations 2020, draft regulations were published. The introductory section of the regulations, and regulation 1, suggest the regulations are going to come into effect in October.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/912858/covid-and-flu-draft-statutory-instrument.pdf
Strikes me that this would be a good time for the UK government to announce another safe, well-tolerated treatment for Covid that can be used alongside dexamethasone, the corticosteroid recommended by the RECOVERY trial.
There is a Nature communication from 2018 suggesting that it may be possible to reverse the impairment of "innate and acquired antiviral immune responses" caused by a (different) corticosteroid through treatment with interferon beta, https://www.nature.com/articles/s41467-018-04574-1
This won't be news to Synairgen because one of the authors is a consultant to the company.
I know there's still a lot of uncertainty, but it's starting to feel like SNG001 may be the right drug, in the right place, at the right time.
Just found an article published in Nature this week "Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients" at https://www.nature.com/articles/s41392-020-00306-4
The conclusion makes interesting reading:
"Overall, Hadjadj et al. identified an impaired type I IFN response, characterized by no IFN-ß and low IFN-a production and activity, should be a hallmark of severe COVID-19. Clinically, type I IFN deficiency is associated with hyperinflammation driven by NF-?B and lower viral clearance. The authors indicated that IFN response is possible to incorporate as an indication to assess early severe COVID-19. The application of IFN administration and targeted anti-inflammatory therapies may aid in the development of improved treatments to overcome SARS-CoV-2 infection."
There was an old man called Parsley
He saved and invested quite smartly
In Synairgen he went long
It went for a song
And now he's living it largely
Parsley, contrary view is that behind the scenes there’s a negotiation going on between RM and a bunch of pharma c level execs like this https://m.youtube.com/watch?v=1-mOKMq19zU
Who knows...
Sorry - should say that article is from 2019 and doesn’t refer to SNG001 in case anyone gets too excited - just the kind of drugs that are appropriate for PRIME.
Pmjh, not sure what you do for a living, but you have a real talent for finding information - thank you.
There’s an article on PRIME at https://pharmaintelligence.informa.com/resources/product-content/only-one-in-seven-prime-applications-meet-ema-test which suggests that SNG001 is the kind of drug that might make the grade (assuming that Synairgen has applied of course).
Synairgen won’t manufacture SNG001 itself - that’s done by contract drug manufacturers (there are big capital costs). Synairgen’s model is R&D and licensing.
Just catching up ...
Macosta, congratulations! Going by your recent posts (below), you must have got at least £3,875,000 for your shares. Life changing stuff!
I guess it will be pretty difficult for you to be objective about Synairgen given how much you've made!
The low on 25 August was £2.02 so 500k shares @ £2.02 = £1,010,000
The low on 27 August was £1.91 so 1.5m shares @ £1.91 = £2,865,000
24 August:
"I first bought at 8p and last added at 186
Im currently sitting on 2 million shares in SNG and by the looks of it Im cashing in tomorrow or by the end of the week if I don't see a RNS from them."
24 August:
"The last time I bought was at 186 and I now hold a total 2 million shares in SNG."
25 August:
"I sold a quarter of my holding today and if we have the same drama tomorrow as we did today wirh the SP going so low, I will sell the rest of my holding. "
27 August:
"Just got home.
Been out celebrating, sold my last shares in SNG. Good luck everyone.
...and yes, I bought some @ 8p and 30p and 90p and £1.86
The lack of news/updates from SNG looked to me like an arrogant company with no consideration for their investors or maybe they just light weight and not really the pharma one invest in.
Whatever, I'm out."
See we hit 174p very briefly - I guess that may be to pick up shares where stop losses have been set at 175p?
Hopefully no-one round here has any stop losses set (learnt the hard way with another AIM share unfortunately).
I’m a bit lost. You said that this would apply during trials only?
The inclusion criteria for the trial are listed at https://clinicaltrials.gov/ct2/show/NCT04385095
Being a shareholder is not one of the inclusion criteria, nor should it ever be.
Anyway, will draw a line under this here.
Hope you don’t need SNG001 but, if you do, that you get a place on the trial.
Annoyed?
Right, now imagine turning up to the hospital to find out that your kid/parent can’t be offered SNG001 as part of a trial because a shareholder (with less clinical need) has got a reserved spot.
Thankfully that’s not how trial subjects are selected.